Skip to content

Pinnacle Metal-on-Metal 522 Post-Market Surveillance Study

Cross-Sectional, Multi-Center Evaluation of 8 Year Metal Ion Trends for Pinnacle MoM System Used in Primary Hip Arthroplasty

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01828801
Enrollment
276
Registered
2013-04-11
Start date
2013-03-31
Completion date
2016-08-31
Last updated
2016-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adverse Local Tissue Reaction, Metal Ions, Pinnacle Metal-on-Metal, Revised Pinnacle Metal-on-Metal, Total Hip Arthroplasty

Keywords

Adverse Local Tissue Reaction, Metal Ions, Serum, Whole Blood, Metal-on-Metal, Total Hip Arthroplasty

Brief summary

The purpose of this clinical study is to evaluate blood metal ion levels as a function of time of implantation for the Pinnacle Acetabular MoM system.

Interventions

DEVICEPinnacle Metal-on Metal

All patients that are post-operative will have undergone total hip arthroplasty with the Pinnacle Metal-on-Metal device

Sponsors

DePuy Orthopaedics
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

1. Able to (or capable of) provide written, voluntary consent to participate in the clinical investigation 2. Is willing and able to return for all protocol defined clinic visits 3. Subject has a combination of the following implants in the study hip (unless in pre-op cohort): 1. Pinnacle acetabular shell with or without Gription TM porous coating 2. M-specification cobalt-chrome femoral head or aSphere M-specification cobalt-chrome femoral head 3. Ultamet metal insert 4. One of the following stems i. S-ROM ii. Corail iii. Tri-Lock iv. AML v. Summit vi. Prodigy vii. C-Stem 4. Subject has high quality films available for review that were taken within 12 months of the primary surgery of the following views: 1. Standing AP-Pelvis 2. Standing AP-Proximal Femur (if this view is not available but the AP-Pelvis shows the entire implant and greater trochanter, that is also acceptable) 3. Lauenstein Lateral Proximal Femur (Lateral-Femur)

Exclusion criteria

1. The subject refuses to allow their medical records to be inspected by the Sponsor, representatives of the Sponsor, the medical office staff and/or representatives from FDA 2. The implanted hip components in the study hip (exclusive of cement), are not all DePuy components (unless in pre-op cohort) 3. The primary procedure occurred greater than 8 (eight) years ago (unless in pre-op cohort) 4. FOR PRE-OPERATIVE COHORT ONLY: the subject has a MoM contralateral hip 5. FOR PRE-OPERATIVE COHORT ONLY: the subject is undergoing a revision of the Ipsilateral hip

Design outcomes

Primary

MeasureTime frameDescription
Change in Chromium serum ion level across time intervalsPre-operatively through 8 yearsTo compare the chromium serum ion levels in the patient population from pre-operatively through 8 years post-operatively in a 1-way ANOVA. This is a cross-sectional study so each time interval (pre-operatively through 8 years post-operatively) will be a different cohort of patients.
Change in Chromium whole blood ion level across time intervalsPre-operatively through 8 yearsTo compare the chromium whole blood ion levels in the patient population from pre-operatively through 8 years post-operatively in a 1-way ANOVA. This is a cross-sectional study so each time interval (pre-operatively through 8 years post-operatively) will be a different cohort of patients.
Change in Cobalt serum ion level across time intervalsPre-operatively through 8 yearsTo compare the cobalt serum ion levels in the patient population from pre-operatively through 8 years post-operatively in a 1-way ANOVA. This is a cross-sectional study so each time interval (pre-operatively through 8 years post-operatively) will be a different cohort of patients.
Change in Cobalt whole blood ion level across time intervalsPre-operatively through 8 yearsTo compare the cobalt whole blood ion levels in the patient population from pre-operatively through 8 years post-operatively in a 1-way ANOVA. This is a cross-sectional study so each time interval (pre-operatively through 8 years post-operatively) will be a different cohort of patients.

Secondary

MeasureTime frameDescription
Ion levels among revised subjectsPre-operatively through 8 years post-operativelyTo compare cobalt and chromium ion level (prior to revision) vs. baseline for subjects who are revised.
Harris Hip and HOOS analysis for pain, function and total scoreThough 8 years post-operativelyTo identify the incidence of pain or functional symptoms among unrevised subjects with a Harris Hip and HOOS evaluation. To compare cobalt and chromium ion levels for unrevised subject who are exhibiting pain or functional symptoms vs. unrevised subjects who are not exhibiting pain or functional symptoms.
To determine the association of adverse events with elevated ion levelsThrough 8 years post-operativelyTo investigate the association of adverse events with elevated cobalt and chromium ion levels. For each respective adverse event, to compare cobalt and chromium ion levels for subjects who have vs. subjects who have not exhibited the adverse event. For each respective adverse event category, to present summary statistics of cobalt and chromium ion levels for subjects who have vs. subjects who have not exhibited the adverse event, stratified by post-op time cohort.
TrendingThrough 8 years post-operativelyTrends (over time since initial implant) will be evaluated for: 1) revisions (survivorship), 2) adverse events, 3) pain or functional symptoms (via Harris Hip and HOOS evaluations), 4) incidence of ALTR in unrevised subjects
Patient history and demographics and association with outcomesThroughout 8 years post-operativelyPatient demographic and subject history will be evaluated for association with: 1) higher metal ion levels and 2) risk of revision.
Poolability of data across stem typesPre-operatively through 8 years post-operativelyWithin each of the primary analyses, the poolability of data across stem types will be confirmed with a 2-way ANOVA model in which both time interval and stem type are independent variables.
Metal ion levels and association with reason for revisionThrough 8 years post-operativelyTo compare cobalt and chromium levels across the different reasons for revision.
Comparison of metal ion levels across subjects with vs. without ALTRThrough 8 years post-operativelyCobalt and Chromium ion levels will be compared for unrevised subjects who were not diagnosed with an ALTR vs. unrevised subject who were diagnosed with an ALTR.
Ion level vs. baseline for ALTR subjectsThrough 8 years post-operativelyTo compare cobalt and chromium ion level vs. baseline for subject who are diagnosed with ALTR.
Ion level change from first measurement for ALTR subjectsThrough 8 years post-operativelyCobalt and chromium ion levels will be compared from first measurement to the time of revision (prior to revision) or the time of last follow-up visit in the study, whichever comes first, for subjects who are diagnosed with an ALTR.
Modes and causes of implant failureThrough 8 years post-operativelyTo evaluate modes and causes of implant failure based on an analysis of reasonably available explanted retrieved devices.
Incidence of adverse local tissue reaction (ALTR)Pre-operatively through 8 years post-operativelyTo determine trends in the incidence of ALTR over time.
Implant survivorshipThrough 8 years post-operativelyTo determine implant survivorship, where an implant is considered to be surviving when none of the total hip replacement (THR) system components have been removed or replaced, so that the original system with metal-on-metal (MoM) articulating surfaces remains intact. Implant survivorship will be analyzed in two ways: 1) for all revisions (for any reason) and 2) for revisions due to ALTR.
To identify the incidence of ALTR among unrevised subjectsThrough 8 years post-operativelyTo identify the incidence of ALTR among unrevised subjects through physical examination and imaging.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026